Breast Cancer: Recurrent Genomic Alterations: Difference between revisions
mNo edit summary |
No edit summary |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
'''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer''' Table derived from Geiersbach et al., 2018 [ | '''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics.<ref>{{Cite journal|last=Geiersbach|first=Katherine B.|last2=Chen|first2=Hui|last3=Emmadi|first3=Rajyasree|last4=Haskell|first4=Gloria T.|last5=Lu|first5=Xinyan|last6=Liu|first6=Yajuan J.|last7=Swisshelm|first7=Karen|date=2020-06|title=Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group|url=https://pubmed.ncbi.nlm.nih.gov/32087595|journal=Cancer Genetics|volume=244|pages=11–20|doi=10.1016/j.cancergen.2020.02.002|issn=2210-7762|pmid=32087595}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Alteration''' | |'''Alteration''' | ||
|'''Relevant Gene(s)''' | |'''Relevant Gene(s)''' | ||
|'''CGC Evidence Level''' | |'''CGC Evidence Level'''† | ||
|'''Subgroup Association(s)''' | |'''Subgroup Association(s)''' | ||
|- | |- | ||
| Line 71: | Line 71: | ||
|METABRIC IntClust1, ER Positive | |METABRIC IntClust1, ER Positive | ||
|} | |} | ||
Abbreviations: TNBC, triple negative breast cancer. | † See table below Table 2 for CGC Evidence levels | ||
Abbreviations: TNBC, triple negative breast cancer; LOH, loss of heterozygosity. | |||
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [ | '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics. | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Gene(s)''' | |'''Gene(s)''' | ||
|'''CGC Evidence Level''' | |'''CGC Evidence Level'''† | ||
|'''Clinical Significance and Subgroup Association(s)''' | |'''Clinical Significance and Subgroup Association(s)''' | ||
|'''Therapy Implication(s)''' | |'''Therapy Implication(s)''' | ||
| Line 91: | Line 93: | ||
|PARP inhibitors (germline) | |PARP inhibitors (germline) | ||
|- | |- | ||
|''[[ | |''[[BRCA1]], [[BRCA2]]'' | ||
|1 | |1 | ||
|Often hereditary risk; TNBC | |Often hereditary risk; TNBC | ||
| Line 234: | Line 236: | ||
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. | Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. | ||
'''Cancer Genomics Consortium Levels of Evidence''' | †'''Cancer Genomics Consortium Levels of Evidence''' | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Tier''' | |'''Tier''' | ||
| Line 258: | Line 260: | ||
'''Table 3 - Genes with known hereditary risk associations in breast cancer''' Table derived from Geiersbach et al., 2018 [ | '''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics. | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Gene''' | |'''Gene''' | ||
| Line 269: | Line 271: | ||
|TNBC | |TNBC | ||
|- | |- | ||
|''BRCA1'' | |''[[BRCA1]]'' | ||
|[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | |[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | ||
|- | |- | ||
|''BRCA2'' | |''[[BRCA2]]'' | ||
|[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | |[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | ||
|- | |- | ||
| Line 306: | Line 308: | ||
|} | |} | ||
Abbreviations: TNBC, triple negative breast cancer. | Abbreviations: TNBC, triple negative breast cancer. | ||
==Reference== | |||
<references /> | |||